Table 1

Effects of α-tocopherol, calpeptin, and quinacrine upon the antiproliferative effects of 3 μM AEA and 2-AG in C6 glioma cells

Test Compound	Cell Number (× 10³ well⁻¹)
Test Compound	Control	AEA (3 μM)	2-AG (3 μM)
μM
α-Tocopherol
0	32.6 ± 1.2 [5]	9.5 ± 0.73^1-a [5]	12.7 ± 1.2^1-a [4]
0.1	32.3 ± 1.3 [5]	34.1 ± 1.3^1-b [5]	30.8 ± 1.3^1-b [4]
10	33.3 ± 1.9 [5]	35.0 ± 1.8^1-b [5]	33.9 ± 2.0^1-b [4]
Calpeptin
0	30.4 ± 0.92 [5]	9.8 ± 0.50^1-a [5]	13.6 ± 1.1^1-a [4]
0.1	32.5 ± 1.7 [5]	9.5 ± 1.1 [5]	13.5 ± 1.6 [4]
10	28.6 ± 0.54 [5]	21.1 ± 4.1^1-b [5]	29.9 ± 1.6^1-b [4]
Quinacrine
0	32.6 ± 1.2 [5]	9.5 ± 0.73^1-a [5]	12.7 ± 1.2^1-a [4]
0.01	31.6 ± 2.0 [5]	8.2 ± 0.80 [5]	7.3 ± 1.8 [4]
1	27.3 ± 2.7 [3]	6.7 ± 2.1 [5]	10.8 ± 3.3 [4]

C6 glioma cells were treated daily for 4 days with the concentrations of compounds shown, as described under Experimental Procedures. Shown are means ± S.E.M., with the number of experiments given in brackets.

↵1-a p < 0.001 versus the corresponding control values in the absence of α-tocopherol, quinacrine, or calpeptin.
↵1-b p < 0.001 versus the corresponding values for the same AEA/2-AG treatment in the absence of α-tocopherol or calpeptin.